Pfizer, Inc.

Pfizer Receives Corporate Responsibility Award for Emergency Response Relief

November 11, 2006

NEW YORK– The International Rescue Committee (IRC) recognized fifty years of partnership in disaster response by honoring Pfizer with its Corporate Responsibility Award. The award was presented at the IRC’s 2006 Freedom Award Dinner. This longstanding relationship has been important in meeting the needs of people who are the victims and survivors of disasters to restore and rebuild their lives.

“Pfizer has been one of the IRC’s most generous and reliable corporate supporters,” said John C. Whitehead, Chairman Emeritus of the IRC. “In one global emergency after another, Pfizer’s contributions have helped save countless lives. We are grateful to them.”

“The IRC has a long history and tremendous reputation for its capacity to respond to humanitarian crises and deploy needed aid to those who are suffering,” said Robert Mallett President of the Pfizer Foundation and Senior Vice President of Worldwide Stakeholder Alliances, Philanthropy and Corporate Citizenship. “We are pleased to receive this award and the fifty years of partnership with the IRC.”

Pfizer’s partnership with IRC began in 1956 by providing emergency medicines and health products to refugees in Hungary. From the public health challenges of a community torn by civil conflict to the tsunami that struck South East Asia, Pfizer has partnered with the IRC to mobilize resources that provided immediate humanitarian relief and supported rebuilding efforts.

Today, the company and IRC collaborate on efforts to build healthcare capacity and improve healthcare delivery to patients in Africa and Asia through Pfizer’s Global Health Fellows program. The Global Health Fellows program sends Pfizer colleagues to work with non-governmental organizations and other partners on public health assignments in developing countries. Global Health Fellows have been placed by the IRC at the Mae Tao Clinic in Thailand and at the Kakuma Refugee Camp in Kenya.

Pfizer Partnership Initiatives:

Global Health Fellows – The program sends Pfizer colleagues on assignments to work with non-governmental and multi-lateral organizations addressing HIV/AIDS, tuberculosis, malaria.

Since 2003, more than 100 Fellows have been selected to work with 23 non-governmental organizations in 29 countries to deliver healthcare and health system support to those in need around the world.

Infectious Diseases Institute – Pfizer partners with the Academic Alliance Foundation, Makerere University, Pangaea Global AIDS Foundation, the Infectious Diseases Society of America, and other organizations to support training and treatment activities of the Infectious Diseases Institute (IDI) in Kampala, Uganda. This regional training and treatment center is empowering the local healthcare providers to care for a population desperately in need of HIV/AIDS treatment and to train others.

Since 2004, the IDI has trained more than 1,000 healthcare providers from 22 African countries.

The center has delivered care to more than 19,000 patients so far.

IDI is also partnering with Exxon/Mobil to expand training programs to include the latest advances in malaria diagnosis, treatment and patient care.

Diflucan Partnership Program – Diflucan® (fluconazole), an antifungal that treats two fungal opportunistic infections associated with AIDS, is provided free of charge to governmental and non-governmental organizations in developing countries.

The program has donated approximately $375 million in medicine to organizations who treat HIV positive patients with life-threatening fungal infections. The program is active in 47 countries hardest hit by HIV/AIDS.

Since 2000, the Diflucan Partnership Program supported the training of 20,000 health professionals in the diagnosis and treatment of fungal opportunistic infections.

International Trachoma Initiative – A public-private partnership dedicated to eliminating trachoma, the world’s leading cause of preventable blindness, through health worker training, patient education and donations of the antibiotic, Zithromax® (azithromycin).

The ITI has given 37 million treatments of Zithromax® (azithromycin) to trachoma patients in 12 countries as part of the WHO SAFE strategy that combines prevention and treatment. Since 1998 the program has supported the training of thousands of health workers around the world who, in turn, have completed more than 220,000 surgeries to treat advanced cases of trachoma.